<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02793557</url>
  </required_header>
  <id_info>
    <org_study_id>FCS-001</org_study_id>
    <nct_id>NCT02793557</nct_id>
  </id_info>
  <brief_title>Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Trial of FOL-005 to Investigate Clinical Safety and Effect on Hair Growth in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Follicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Follicum AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate clinical safety and effect on hair growth of FOL-005 in healthy
      volunteers. The study is divided in two parts, a single ascending dose (SAD) part and a
      multiple dose (MD) part.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAD part:

      A total of 3 weeks dosing, the two lowest concentrations in week 1, dose 3 at week 2 and
      finally dose 4 at week 3.

      MD part:

      In total 12 weeks of dosing where group A will be dosed twice weekly and group B three times
      weekly

      Each injection will be administered into one of five of the six randomized areas (10 cm
      apart, left and right side) from the subject's defined investigational skin areas. One area
      will be completely untreated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability by assessing the number and severity of adverse events after intradermal applications of FOL-005 in healthy subjects</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of FOL-005, as compared to placebo, with respect to number of hairs/cm2</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of FOL-005, as compared to placebo, with respect to proportion of telogen hairs</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of FOL-005, as compared to placebo, with respect to proportion of anagen hairs</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hypertrichosis</condition>
  <condition>Alopecia</condition>
  <condition>Hirsutism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOL-005: Solution 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOL-005: Solution 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOL-005: Solution 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOL-005: Solution 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOL-005</intervention_name>
    <description>Intradermal injection of 50 μl solution</description>
    <arm_group_label>FOL-005: Solution 1</arm_group_label>
    <arm_group_label>FOL-005: Solution 2</arm_group_label>
    <arm_group_label>FOL-005: Solution 3</arm_group_label>
    <arm_group_label>FOL-005: Solution 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male, aged 18-45 years

          -  Clinically visible terminal hair growth on thighs

        Exclusion Criteria:

          -  Damaged skin in or around test sites

          -  History of any acute (e.g. acute infections) or chronic illness or known skin cancer
             that might confound the results of the trial

          -  History or clinical signs of keloids or hypertrophic scars

          -  Immunological disorders such as alopecia areata, and systemic lupus erythematosus

          -  Current or within 2 weeks prior to first dosing use of vasodilating drugs (e.g.
             Pentoxifyllin, nitroglycerine) or anticoagulating drugs (e.g. heparine, cumarines, new
             oral anticoagulants)

          -  Current or within 3 months prior to first dosing use of anti-inflammatory medication,
             corticosteroids or immunosuppressive drugs taken for more than 2 consecutive weeks

          -  Current or within 3 months prior to first dosing use of medication with hair growth
             modifying properties like minoxidil, diazoxid, cyclosporine, antiandrogens

          -  Current or within 12 months prior to first dosing intake of anabolics or 5-alpha
             reductase inhibitors

          -  Current or within one week prior to first dosing use of any topical drugs on the legs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Blume-Peytavi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin Charitéplatz 1 - 10117 Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>July 29, 2017</last_update_submitted>
  <last_update_submitted_qc>July 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Hirsutism</mesh_term>
    <mesh_term>Hypertrichosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

